-
Founded in:
2000-10-20 -
Country:
China -
Address:
Chenglinzhuang Industrial Zone, Tianjin -
Tax NO.:
91120110103738323L -
Registered Funds:
- -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Losartan potassium |
Angiotensin II receptor (AT1 receptor) antagonist, blocks all physiological effects related to angiotensin II, lowers blood pressure, inhibits aldosterone release, reduces potassium loss, and has a mild and transient uricosuric effect.
More
Angiotensin II receptor (AT1 receptor) antagonist, blocks all physiological effects related to angiotensin II, lowers blood pressure, inhibits aldosterone release, reduces potassium loss, and has a mild and transient uricosuric effect. |
50mg | 124750-99-8 | 66 |
| Hydrochlorothiazide |
Diuretics affect the reabsorption of electrolytes by the distal renal tubules, increase the excretion of sodium, chloride, potassium and bicarbonate, and have diuretic and antihypertensive effects.
More
Diuretics affect the reabsorption of electrolytes by the distal renal tubules, increase the excretion of sodium, chloride, potassium and bicarbonate, and have diuretic and antihypertensive effects. |
12.5mg | 58-93-5 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gliclazide |
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.
More
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased. |
21187-98-4 | 22 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| TOLBUTAMIDE |
This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.
More
This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar. |
64-77-7 | 16 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fenbufen |
This product is a long-acting non-steroidal anti-inflammatory drug. After entering the body, it is metabolized into diphenyl ethyl ester, which inhibits the activity of cyclooxygenase and reduces the synthesis of prostaglandins. Animal experiments show that the anti-inflammatory and analgesic effects of this product are weaker than indomethacin, but stronger than aspirin.
More
This product is a long-acting non-steroidal anti-inflammatory drug. After entering the body, it is metabolized into diphenyl ethyl ester, which inhibits the activity of cyclooxygenase and reduces the synthesis of prostaglandins. Animal experiments show that the anti-inflammatory and analgesic effects of this product are weaker than indomethacin, but stronger than aspirin. |
36330-85-5 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fenbufen |
This product is a long-acting non-steroidal anti-inflammatory drug. After entering the body, it is metabolized into diphenyl ethyl ester, which inhibits the activity of cyclooxygenase and reduces the synthesis of prostaglandins. Animal experiments show that the anti-inflammatory and analgesic effects of this product are weaker than indomethacin, but stronger than aspirin.
More
This product is a long-acting non-steroidal anti-inflammatory drug. After entering the body, it is metabolized into diphenyl ethyl ester, which inhibits the activity of cyclooxygenase and reduces the synthesis of prostaglandins. Animal experiments show that the anti-inflammatory and analgesic effects of this product are weaker than indomethacin, but stronger than aspirin. |
36330-85-5 | 9 |